Senolytics and Senotherapeutics in Neurodegeneration

Migration, Crosslink

📖

Senolytics and Senotherapeutics in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-senolytics

📖 Wiki Page

therapeutic1677 wordssynced 2026-04-02

Senolytics and Senotherapeutics in Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Senolytics and Senotherapeutics in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Name</td>
<td>Senolytics and Senotherapeutics in Neurodegeneration</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Senotherapeutics aim to reduce disease-driving senescent cell burden or suppress the inflammatory senescence-associated secretory phenotype (SASP). In neurodegeneration, senescent [astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia), oligodendrocyte-lineage cells, and vascular cells can amplify chronic inflammation, disrupt synaptic homeostasis, and accelerate [tau pathology](/mechanisms/tau-pathology), [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), and neuronal loss. This has made senolytics a high-priority translational strategy in aging-related disorders, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and 4R tauopathies.

Senescence Biology Relevant to Neurodegeneration

Core Programs

...

Senolytics and Senotherapeutics in Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Senolytics and Senotherapeutics in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Name</td>
<td>Senolytics and Senotherapeutics in Neurodegeneration</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Senotherapeutics aim to reduce disease-driving senescent cell burden or suppress the inflammatory senescence-associated secretory phenotype (SASP). In neurodegeneration, senescent [astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia), oligodendrocyte-lineage cells, and vascular cells can amplify chronic inflammation, disrupt synaptic homeostasis, and accelerate [tau pathology](/mechanisms/tau-pathology), [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), and neuronal loss. This has made senolytics a high-priority translational strategy in aging-related disorders, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and 4R tauopathies.

Senescence Biology Relevant to Neurodegeneration

Core Programs

Cellular senescence is a persistent stress response driven by DNA damage, mitochondrial stress, telomere attrition, and proteotoxic injury. The state is stabilized by p53/p21 and p16INK4a/Rb programs, alongside anti-apoptotic rewiring (BCL-2, BCL-xL, MCL-1), which creates senolytic vulnerabilities.[@he2017][@zhu2015]

SASP as a Feed-Forward Neuroinflammatory Engine

SASP output varies by cell type and context but commonly includes IL-1beta, IL-6, TNF-alpha, chemokines, and matrix-remodeling factors. In the CNS, this can:

prime and sustain pro-inflammatory [microglia](/cell-types/microglia)
weaken synaptic support from [astrocytes](/cell-types/astrocytes)
reduce remyelination capacity through oligodendrocyte-lineage dysfunction
impair [blood-brain barrier](/blood-brain-barrier) integrity and neurovascular coupling

This produces a reinforcing loop: neurodegenerative pathology induces senescence; senescent cells increase inflammatory and proteostatic stress; pathology progression accelerates.[@baker2018][@musi2018][@bussian2018]

Cell Types with Strong Signal

[Astrocytes](/entities/astrocytes): Senescent astrocytes lose glutamate buffering and trophic support while increasing inflammatory signaling.[@bhat2012]
[Microglia](/cell-types/microglia): Dystrophic/senescent [microglia](/cell-types/microglia-neuroinflammation) show impaired homeostatic phagocytosis and altered inflammatory tone, linked to [tau](/proteins/tau) pathology burden.[@streit2009]
Oligodendrocyte progenitors: Senescence-like states can limit remyelination and metabolic support in vulnerable circuits.[@zhang2019]
Endothelial/perivascular cells: Vascular senescence contributes to [BBB](/entities/blood-brain-barrier) leak and peripheral immune trafficking.[@yamazaki2016]

Mermaid diagram (expand to render)

Senolytic and Senomorphic Modalities

Dasatinib + Quercetin (D+Q)

D+Q is the most clinically advanced intermittent senolytic regimen. Dasatinib inhibits tyrosine kinase survival pathways, while quercetin targets PI3K-related and anti-apoptotic signaling; the combination broadens hit-rate across heterogeneous senescent phenotypes.[@zhu2015][@zhu2017] Pilot CNS work demonstrates that oral dosing can produce measurable CNS exposure in humans, supporting biological plausibility for neurodegenerative use.[@gonzales2023]

Fisetin

Fisetin is a flavonoid with senotherapeutic effects in preclinical systems and early human aging/frailty studies. It is often positioned as a lower-complexity alternative because it does not require a prescription oncology kinase inhibitor, though neurodegeneration-specific efficacy remains unproven.[@yousefzadeh2018][@justice2019]

Navitoclax and BCL-xL Axis Agents

Navitoclax (ABT-263) strongly validates the BCL-2/BCL-xL dependency model for senescent-cell [apoptosis](/mechanisms/apoptosis), but thrombocytopenia has limited chronic clinical deployment and motivates next-generation selective approaches.[@chang2016]

Senomorphics

Senomorphics aim to suppress SASP without eliminating senescent cells. Relevant classes include [mTOR](/mechanisms/mtor-signaling-pathway) modulators and anti-inflammatory pathway regulators, and can be combined with senolytics conceptually to reduce rebound inflammatory tone.[@kirkland2020][@acosta2013]

Preclinical Evidence Across Disease Contexts

Tauopathy and Alzheimer's-Relevant Models

A central mechanistic anchor is the demonstration that clearing p16-positive glial senescent cells prevents [tau](/proteins/tau)-dependent neurodegeneration and cognitive decline in tau transgenic mice.[@bussian2018] This result directly supports senescence as a causal driver rather than a passive correlate in proteinopathy progression. Additional work links tau aggregation itself to senescence signatures in human and model systems, strengthening bidirectional causality.[@musi2018]

In amyloid/tau-relevant models, senotherapeutic interventions have been associated with reduced inflammatory load, improved neurogenesis markers, and better behavioral outcomes, although effect sizes vary by model and timing.[@zhang2019][@ogrodnik2021]

Parkinson's and ALS-Relevant Context

Mechanistic translation to [Parkinson's disease](/diseases/parkinsons-disease) and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) is supported by convergent pathways: mitochondrial stress, proteostasis collapse, and neuroimmune dysfunction. The current evidence base is strongest for biological plausibility and weakest for adequately powered disease-modifying clinical outcomes.[@baker2018][@geng2010]

Clinical Translation Status

Alzheimer's-Focused Early Trials

A pilot Alzheimer's trial of D+Q established feasibility and suggested target engagement, including detectable dasatinib in CSF after oral dosing. The study was small and not powered for efficacy, but it remains a key translational milestone.[@gonzales2023]

Broader Senotherapeutic Clinical Programs

Senolytic and senomorphic programs have proceeded in non-neurologic indications (frailty, fibrosis, musculoskeletal disease), which helps define dose windows and liabilities relevant to CNS repurposing.[@justice2019][@jeon2017][@gasek2021]

Ongoing Trial Design Priorities for Neurodegeneration

High-value trial architecture should include:

biomarker-defined cohorts (fluid and imaging)
staged exposure (induction then maintenance pulses)
explicit adverse-event adjudication for cytopenia, bleeding, and infection risk
pathway pharmacodynamics (SASP and senescence-burden markers)

Blood-Brain Barrier and CNS Delivery Constraints

BBB transport is a central bottleneck for senotherapeutics. Translational risk is not only whether compounds cross, but whether adequate concentrations are achieved in target cell niches without systemic toxicity. Key constraints include:

variable oral pharmacokinetics and high inter-patient exposure variance
active efflux transport and limited parenchymal penetration
uncertainty about intracellular concentrations in senescent glia vs endothelium
need for pulse schedules that balance CNS effect with hematologic safety

Potential mitigation strategies include medicinal chemistry for CNS penetration, intermittent schedule optimization, and pairing with validated [CNS drug delivery methods](/mechanisms/cns-drug-delivery-methods).[@yamazaki2016][@sweeney2018]

Industry and Company Landscape

Unity Biotechnology and First-Wave Lessons

Unity Biotechnology helped establish mainstream clinical momentum for senotherapeutics but also highlighted failure modes in target selection and indication fit. The main takeaways for neurodegeneration are:

target biology must be tightly linked to disease-driving senescence nodes
local pharmacology and tissue distribution can dominate outcomes
biomarker strategy is mandatory, not optional

Other Active or Adjacent Players

The broader ecosystem includes companies and programs pursuing senolytics, senomorphics, or rejuvenation-adjacent interventions (for example, approaches involving partial epigenetic reprogramming or systemic aging pathway modulation). See [Longevity and Rejuvenation Therapies](/therapeutics/longevity-rejuvenation-therapies) for cross-company landscape context.

Practical Safety and Monitoring Considerations

For candidate neurodegeneration use, the risk frame is dominated by:

cytopenia and bleeding risk (especially with BCL-2-family targeting)
hepatic/renal exposure variability
polypharmacy interactions in older adults
fragile functional reserve and fall risk

Recommended baseline and cycle-level checks typically include CBC with differential, liver/renal panels, ECG when relevant, and structured adverse-event diaries. Intermittent schedules may improve tolerability but require disciplined monitoring.[@justice2019][@chang2016][@jeon2017]

Evidence Interpretation

Strengths

strong mechanistic coherence linking senescence, SASP, and neurodegeneration
causal preclinical data in tauopathy-relevant systems
early human feasibility and CNS exposure data for D+Q

Limitations

limited powered efficacy trials in CNS diseases
uncertain comparability between peripheral and CNS senescence markers
dose, schedule, and responder phenotype still unresolved

Research Priorities

Define minimal pharmacodynamic biomarker sets for CNS senescence response.

Stratify likely responders by inflammatory profile and proteinopathy stage.

Build head-to-head translational comparisons (D+Q vs fisetin-like approaches).

Integrate senotherapeutics with pathway-complementary interventions (for example, [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration) and mitochondrial support programs).

[Senolytic Therapies for CBS and PSP](/therapeutics/senolytics-neurodegeneration)
[Cellular Senescence in Neurodegeneration](/cellular-senescence-in-neurodegeneration)
[SASP in Neurodegeneration](/mechanisms/sasp-senescence-associated-secretory-phenotype)
[Blood-Brain Barrier Biology](/mechanisms/blood-brain-barrier-biology)
[CNS Drug Delivery Methods](/mechanisms/cns-drug-delivery-methods)
[Longevity and Rejuvenation Therapies](/therapeutics/longevity-rejuvenation-therapies)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Kirkland JL, Tchkonia T, Senolytic drugs: from discovery to translation (2020)](https://pubmed.ncbi.nlm.nih.gov/32686219/)

[Baker DJ, Petersen RC, Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives (2018)](https://pubmed.ncbi.nlm.nih.gov/29457783/)

[Coppé JP, Desprez PY, Krtolica A, Campisi J, The senescence-associated secretory phenotype: the dark side of tumor suppression (2010)](https://pubmed.ncbi.nlm.nih.gov/20078217/)

[He S, Sharpless NE, Senescence in health and disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28575665/)

[Zhu Y, Tchkonia T, Pirtskhalava T, et al, The Achilles' heel of senescent cells: from transcriptome to senolytic drugs (2015)](https://pubmed.ncbi.nlm.nih.gov/25754370/)

[Musi N, Valentine JM, Sickora KR, et al, Tau protein aggregation is associated with cellular senescence in the brain (2018)](https://pubmed.ncbi.nlm.nih.gov/29795462/)

[Bussian TJ, Aziz A, Meyer CF, et al, Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline (2018)](https://pubmed.ncbi.nlm.nih.gov/30271983/)

[Bhat R, Crowe EP, Bitto A, et al, Astrocyte senescence as a component of Alzheimer's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22895512/)

[Streit WJ, Braak H, Xue QS, Bechmann I, Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19408404/)

[Zhang P, Kishimoto Y, Grammatikakis I, et al, Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer's disease model (2019)](https://pubmed.ncbi.nlm.nih.gov/30936558/)

[Yamazaki Y, Baker DJ, Bhatt N, Bhattacharyya A, Vascular cell senescence contributes to blood-brain barrier breakdown (2016)](https://pubmed.ncbi.nlm.nih.gov/27525523/)

[Zhu Y, Tchkonia T, Pirtskhalava T, et al, Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors (2017)](https://pubmed.ncbi.nlm.nih.gov/28635070/)

[Gonzales MM, Garbarino VR, Marber MS, et al, Senolytic therapy to modulate the progression of Alzheimer's disease (SToMP-AD): a pilot clinical trial (2023)](https://pubmed.ncbi.nlm.nih.gov/36802521/)

[Yousefzadeh MJ, Zhu Y, McGowan SJ, et al, Fisetin is a senotherapeutic that extends health and lifespan (2018)](https://pubmed.ncbi.nlm.nih.gov/30279143/)

[Justice JN, Nambiar AM, Tchkonia T, et al, Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study (2019)](https://pubmed.ncbi.nlm.nih.gov/30616998/)

[Chang J, Wang Y, Shao L, et al, Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice (2016)](https://pubmed.ncbi.nlm.nih.gov/26657143/)

[Acosta JC, Banito A, Wuestefeld T, et al, A complex secretory program orchestrated by the inflammasome controls paracrine senescence (2013)](https://pubmed.ncbi.nlm.nih.gov/23945590/)

[Ogrodnik M, Evans SA, Fielder E, et al, Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice (2021)](https://pubmed.ncbi.nlm.nih.gov/30307012/)

[Geng YQ, Guan JT, Xu MY, et al, Senescence-associated beta-galactosidase activity expression in aging hippocampal neurons (2010)](https://pubmed.ncbi.nlm.nih.gov/20837066/)

[Jeon OH, Kim C, Laberge RM, et al, Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment (2017)](https://pubmed.ncbi.nlm.nih.gov/28099988/)

[Gasek NS, Kuchel GA, Kirkland JL, Xu M, Strategies for targeting senescent cells in human disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33811810/)

[Sweeney MD, Sagare AP, Zlokovic BV, Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29955131/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-senolytics

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-senolytics
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ac97cd68964c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-senolytics'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

543

Outgoing

715

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Senolytics and Senotherapeutics in Neurodegeneration

Senolytics and Senotherapeutics in Neurodegeneration

Introduction

Senescence Biology Relevant to Neurodegeneration

Core Programs

Senolytics and Senotherapeutics in Neurodegeneration

Introduction

Senescence Biology Relevant to Neurodegeneration

Core Programs

SASP as a Feed-Forward Neuroinflammatory Engine

Cell Types with Strong Signal

Senolytic and Senomorphic Modalities

Dasatinib + Quercetin (D+Q)

Fisetin

Navitoclax and BCL-xL Axis Agents

Senomorphics

Preclinical Evidence Across Disease Contexts

Tauopathy and Alzheimer's-Relevant Models

Parkinson's and ALS-Relevant Context

Clinical Translation Status

Alzheimer's-Focused Early Trials

Broader Senotherapeutic Clinical Programs

Ongoing Trial Design Priorities for Neurodegeneration

Blood-Brain Barrier and CNS Delivery Constraints

Industry and Company Landscape

Unity Biotechnology and First-Wave Lessons

Other Active or Adjacent Players

Practical Safety and Monitoring Considerations

Evidence Interpretation

Strengths

Limitations

Research Priorities

See Also

External Links

Allen Brain Atlas Resources

References

cites (2)

💬 Discussion

📗 Cite This Artifact

Senolytics and Senotherapeutics in Neurodegeneration

Senolytics and Senotherapeutics in Neurodegeneration

Introduction

Senescence Biology Relevant to Neurodegeneration

Core Programs

Senolytics and Senotherapeutics in Neurodegeneration

Introduction

Senescence Biology Relevant to Neurodegeneration

Core Programs

SASP as a Feed-Forward Neuroinflammatory Engine

Cell Types with Strong Signal

Senolytic and Senomorphic Modalities

Dasatinib + Quercetin (D+Q)

Fisetin

Navitoclax and BCL-xL Axis Agents

Senomorphics

Preclinical Evidence Across Disease Contexts

Tauopathy and Alzheimer's-Relevant Models

Parkinson's and ALS-Relevant Context

Clinical Translation Status

Alzheimer's-Focused Early Trials

Broader Senotherapeutic Clinical Programs

Ongoing Trial Design Priorities for Neurodegeneration

Blood-Brain Barrier and CNS Delivery Constraints

Industry and Company Landscape

Unity Biotechnology and First-Wave Lessons

Other Active or Adjacent Players

Practical Safety and Monitoring Considerations

Evidence Interpretation

Strengths

Limitations

Research Priorities

Related Pages

See Also

External Links

Allen Brain Atlas Resources

References

Related Hypotheses

cites (2)

💬 Discussion